肺纤维化TY - JOUR T1 - r分级:一种简单的、可视的工具评估健康相关的生活质量的JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.00917 -2021欧元SP - 2100917 AU Scallan Ciaran AU -链,劳伦AU -海耶斯,詹妮弗盟——Kadura苏哈AU -柯林斯,布丽姬特盟- Ho,劳伦斯AU -位咨询专家,卡罗琳AU - Canestaro,将非盟-科尔布,特发性肺纤维化(IPF)患者存在健康相关生活质量受损(HRQoL)。已经开发了一些工具来客观评估该患者群体的HRQoL，但没有一种工具在常规临床实践中使用。目的开发一种快速、特异性的工具，可用于IPF患者的常规门诊访问。方法开发一种新颖而简单的5项数值评分表(NRS)，并与之前两种已验证的工具进行比较。在ILD中心连续招募100名IPF患者，完成R-Scale-PF、Kings Brief间质性肺病问卷(K-BILD)和EuroQol五维五水平问卷(eq - 5d - 5l)，以及肺功能和6分钟步行测试。100例患者均成功完成3项HRQoL工具，其中53例在随访时再次完成。内部一致性高(Cronbach's α 0.825)，地板/天花板效应最小。与K-BILD (r=−0.713)和eq - 5d - 5l (r=−0.665)相比，r - pf量表的同时效度为中等至较高。生理测量的同时效度为中等(用力肺活量，r=−0.307,6分钟步行距离，r=−0.383)。当比较不同疾病严重程度阶段的分数时，r - pf量表显示了良好的已知组效度。结论R-Scale-PF与K-BILD、eq - 5d - 5l有良好的相关性。 It is hoped that this novel simple NRS tool subject to validation in patients from other centers will provide the opportunity to objectively measure HRQoL in routine clinical practice for patients with IPF.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Scallan has nothing to disclose.Conflict of interest: Dr. Strand has nothing to disclose.Conflict of interest: Dr. Hayes has nothing to disclose.Conflict of interest: Dr. Kadura has nothing to disclose.Conflict of interest: Dr. Collins reports personal fees from Boehringer Ingelheim, outside the submitted work; .Conflict of interest: Dr. Ho has nothing to disclose.Conflict of interest: Dr. Spada has nothing to disclose.Conflict of interest: Dr. Canestaro has nothing to disclose.Conflict of interest: Dr. Kolb reports grants from Canadian Pulmonary Fibrosis Foundation, other from Roche, other from Boehringer Ingelheim, grants from Canadian Institute for Health Research, grants and personal fees from Boehringer Ingelheim, grants and personal fees from Roche, grants and personal fees from Liminal, other from European Respiratory Journal, personal fees from Third Pole, personal fees from MitoImmune, grants and personal fees from Pieris, personal fees from Abbvie, personal fees from DevPro Biopharma, personal fees from Horizon, personal fees from Algernon, personal fees from CSL Behring, outside the submitted work; .Conflict of interest: Dr. Raghu has nothing to disclose. ER -